{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-032160","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2024-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.401870+00:00","generated_at":"2026-06-06T04:22:55.455964+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AlloVir receives Nasdaq notice of non-compliance; bid price below $1.00 for 30 days","bullets":["Received Nasdaq letter on Feb 9, 2024, for bid price < $1.00 over 30 consecutive business days.","Has 180 days (until Aug 7, 2024) to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant, may get additional 180 days if certain criteria are met.","Evaluating options including reverse stock split to regain compliance.","Common stock continues trading on Nasdaq Global Select under symbol ALVR for now."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-032160","json":"https://secwatch.observer/filing/0001193125-24-032160.json","markdown":"https://secwatch.observer/filing/0001193125-24-032160.md","text":"https://secwatch.observer/filing/0001193125-24-032160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312524032160/0001193125-24-032160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312524032160/d764004d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:22:55.455964+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60464f500f5c407f678c4b226d5a1e76ea3f19ba","claim":"Kalaris Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"February 9, 2024, AlloVir, Inc. (“AlloVir”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of AlloVir’s common stock was below $1.00 per share for 30 consecutive business days, and that, therefore, AlloVir is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The notice from Nasdaq has no immediate effect on the listing of AlloVir’s common stock, and the common stock will continue to be listed on the Nasdaq Global Select Market under the","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312524032160/0001193125-24-032160-index.htm","confidence":0.99,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}